The case for & against
Bull & Bear analysis
Bearish
Aldera Therapeutics (NASDAQ: ALDX) is focused on developing innovative therapies for ocular and systemic immune-mediated diseases, positioning itself as a potential leader in the treatment of conditions like dry eye disease and ocular cancers. The company is currently emphasizing its lead candidate, Reproxilab, which targets unmet needs in ocular therapies and aims to disrupt the market through rapid efficacy. Aldera operates in a competitive space where effective solutions for ocular conditions are in high demand, particularly following the recent market shift with the introduction of generics.
Bull says
- ↑Phase 3 Reproxilab reduced ocular discomfort (p=0.002), outperforming slow-acting rivals
- ↑Cash reserves >$100M support clinical programs into 2027 without dilutive financing
- ↑High growth potential in the $23B dry eye disease market amid unmet treatment needs
- ↑NDA submission deemed highly comprehensive, reflecting proactive FDA engagement
- ↑Strong momentum factors and robust liquidity support investor entry and exit
- ↑Rapid-acting therapy positioned to capture share from generics and legacy drugs
Bear says
- ↓FY22 net loss of $62M increases funding risk as R&D expenses rise
- ↓Negative earnings yield signals low profitability expectations from investors
- ↓FDA may require two successful trials for label claims, raising regulatory risk
- ↓COVID-19–related trial delays could push back key milestones and launches
- ↓Physician adoption uncertain if Reproxilab lacks clear clinical differentiation
- ↓Elevated leverage risk and declining analyst sentiment weigh on valuation
Investment themes with ALDX
Biotech↑ +0.07%
Genetic and drug innovations driving medical breakthroughs
ABBV · AMGN · TMO
Earnings Call · Q1 2022 · Mgmt. Guidance
Updated 08-10-2026neutral
Transcript signals
Bull points
- Based on our current operating plan, we expect our existing cash, cash equivalents, and marketable securities to be sufficient to fund currently projected operating expenses through the end of 2023, including potential new drug application submissions, initial commercialization of Roproxilab, if approved, and continued development of our product candidates in ocular and systemic immune-mediated diseases.
- Based on our current operating plan, we expect our existing cash, cash equivalents, and marketable securities to be sufficient to fund currently projected operating expenses through the end of 2023, including potential new drug application submissions, initial commercialization of Roproxilab, if approved, and continued development of our product candidates in ocular and systemic immune-mediated diseases.
- We're continuing to advance Reproxilab toward an expected mid-year NDA submission in dry eye disease.
Bear points
- Net loss was $16.8 million, or 29 cents per share, compared with a net loss of $11.3 million, or 25 cents per share, for the comparable period of 2021. Losses have resulted from the cost of clinical trials and research and development programs as well as from general and administrative expenses.
- Research and development expenses were $12.2 million compared with $7.7 million for the same period in 2021. The increase of $4.5 million is primarily related to increases in our clinical research and development expenditures. General and administrative expenses were $4.2 million compared with $3.1 million for the same period in 2021. The increase of $1.1 million is primarily due to an increase in consulting expenditures. Total operating expenses were $16.5 million, compared with total operating expenses of $10.8 million for the same period in 2021.
- Net loss was $16.8 million, or 29 cents per share, compared with a net loss of $11.3 million, or 25 cents per share, for the comparable period of 2021. Losses have resulted from the cost of clinical trials and research and development programs as well as from general and administrative expenses.
Read full transcript analysis ›